IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Raltegravir Insulin Sensitivity Study
This study has been completed.
Sponsor:
St Stephens Aids Trust
Information provided by:
St Stephens Aids Trust
ClinicalTrials.gov Identifier:
NCT00531999
First received: September 18, 2007
Last updated: August 13, 2010
Last verified: August 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to look at the effects of two different HIV medications on the body's response to insulin (a hormone that regulates blood sugar levels). This will be done using a method called the 'euglycaemic clamp'
The study will also investigate the effects of these drugs on blood fats and on circulating markers in the blood stream related to blood vessels (vascular inflammation markers).
| Condition | Intervention | Phase |
|---|---|---|
| HIV Infections | Drug: Raltegravir then lopinavir/ritonavir Drug: Lopinavir/ritonavir then raltegravir | Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | An Open Label Study of the Impact on Insulin Sensitivity, Lipid Profile and Vascular Inflammation by Treatment With Lopinavir / Ritonavir (400 / 100 mg Twice Daily) or Raltegravir 400 mg Twice Daily in HIV Negative Male Volunteers. |
Resource links provided by NLM:
Further study details as provided by St Stephens Aids Trust:
Primary Outcome Measures:
- Change from baseline in insulin sensitivity by euglycaemic clamp method [ Time Frame: 2 weeks ]
Secondary Outcome Measures:
- Change from baseline in serum levels of fasting cholesterol, triglycerides [ Time Frame: 2 weeks ]
| Enrollment: | 18 |
| Study Start Date: | October 2007 |
| Study Completion Date: | August 2008 |
| Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Raltegravir 400 mg twice daily for the first 14 days of the study. Lopinavir/ritonavir 400/100 mg twice daily for the last 14 days of the study
|
Drug: Raltegravir then lopinavir/ritonavir
raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
|
Active Comparator: 2
|
Drug: Lopinavir/ritonavir then raltegravir
lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
|
Detailed Description:
Subjects will undergo four euglycaemic clamp procedures in order to determine the extent of glucose disposal. The first clamp will be performed prior to the commencement of the first study drug administration, the second one following two weeks of study drug, the third after a two week washout period, prior to commencement of second study drug administration and the fourth after two weeks of the second study drug
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Subjects must have documented negative HIV serology by ELISA and P24 antigen
- Subjects must be clinically well males aged between 18 to 60 years
- Fasting blood glucose, total cholesterol and triglycerides within normal limits
- Hepatic transaminases (AST and ALT) ≤ 3 × upper limit of normal (ULN)
- Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm3; platelets ≥ 50,000/mm3; hemoglobin ≥ 8.0 g/dL)
- Serum amylase ≤ 1.5 × ULN (subjects with serum amylase > 1.5 × ULN will remain eligible if pancreatic lipase is ≤ 1.5 × ULN)
- Sexually active males must use condoms during the course of the study
- Life expectancy ≥ 1 year
- Willing and able to provide informed consent
Exclusion Criteria:
- Subjects with a waist hip ratio > 0.97 or BMI > 28 kg/m2 will be excluded
- Acute or chronic hepatitis B infection (determined by positive hepatitis B surface antigen result at the screening visit)
- Acute or chronic hepatitis C infection (determined by positive hepatitis C antibody result at the screening visit)
- Other metabolic syndrome or disease process in the opinion of the investigator likely to cause marked disturbance in glucose and lipid homeostasis including hypertension
-
Receiving on-going therapy with any of the following:
- Metabolically active medications
- Any lipid-lowering medication
- Hormonal agents (oestrogens or androgens)
- Glucocorticoids
- Beta-blockers
- Thiazide diuretics
- Thyroid preparations
- Psychotropic agents
- Anabolic steroids
- Megestrol acetate
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00531999
Please refer to this study by its ClinicalTrials.gov identifier: NCT00531999
Locations
| United Kingdom | |
| St Stephens Centre, Chelsea & Westminster Hospital | |
| London, United Kingdom | |
Sponsors and Collaborators
St Stephens Aids Trust
Investigators
| Principal Investigator: | Greame Moyle | Chelsea & Westminser Healthcare NHS Trust |
More Information
| Responsible Party: | Dr Graeme Moyle, St Stephen's AIDS Trust |
| ClinicalTrials.gov Identifier: | NCT00531999 History of Changes |
| Other Study ID Numbers: |
SSAT023 |
| Study First Received: | September 18, 2007 |
| Last Updated: | August 13, 2010 |
Keywords provided by St Stephens Aids Trust:
|
Raltegravir Euglycaemic clamp healthy volunteer |
Additional relevant MeSH terms:
|
HIV Infections Insulin Resistance Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Ritonavir Lopinavir |
Raltegravir Potassium Insulin HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors HIV Integrase Inhibitors Integrase Inhibitors Hypoglycemic Agents |
ClinicalTrials.gov processed this record on July 24, 2017